Recruiting

Weight Management App

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT04453072

Conditions

Obesity

Malignant Neoplasm

Eligibility Criteria

Sex: All

Age: 13 - 30

Healthy Volunteers: Accepted

Interventions

Interview

Media Intervention

Questionnaire Administration

Scale Device

Telephone-Based Intervention

Study Details

Brief summary:

This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell transplant. This study may help researchers learn more about how adolescents and young adults can lose weight and develop healthy eating habits.

Conditions

Obesity

Malignant Neoplasm

Study ID

NCT04453072

Start date

Jul 1, 2020

Status verified date

May, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 13 - 30

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Patients with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study
  • Patients must classify as obese, represented as body mass index (BMI) >= 85th percentile for age and gender
  • Patients must also be able to read English since the app intervention is only available in English form
  • No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation
  • PARENT:
  • His/her child meets all inclusion criteria
  • >= 18 years of age
  • Can speak English

Exclusion Criteria:

  • Patients who are < 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are > 100 days post-transplant at their next consultation that falls within the enrollment window
  • Patients whose BMI does not fall under the obese category will be excluded

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Supportive Care (app, scales, coaching, questionnaire)

Patients receive an iPhone with W8Loss2Go app, a body scale and a digital food scale to weigh themselves and food daily. Patients interact with coaches via text messages for 4 days weekly and receive weekly 15 minute phone calls for appointment reminders, emotional support, progress discussion, and follow up on items discussed in a prior visit or phone call. Patients also have telemedicine interviews with the coach lasting 60 minutes at 2 and 4 months to elicit both positive and negative impacts on weight management and to identify barriers such as emotional eating, displacement behaviors, poor coping skills to life stressors, and social challenges. Patients who opt to extend the intervention until month 12 attend an additional telemedicine meeting with the coach. Patients also complete questionnaires over approximately 1.5 hours.

Interventions

Interview

Participate in interviews

Media Intervention

Receive iPhone with W8Loss2Go app

Questionnaire Administration

Complete questionnaires

Scale Device

Receive body scale and food scale

Telephone-Based Intervention

Receive telephone calls

Text Message

Receive text message

Primary outcome measure

  • Change in body mass index (BMI) status [ Time Frame: Baseline up to 12 months ]

Central Contacts and Locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90095

Contacts

Theodore B. Moore

310-794-8929tbmoore@mednet.ucla.edu

Principal Investigator:

Theodore B. Moore

More Information

Sponsor

Jonsson Comprehensive Cancer Center

Last update posted

May 11, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2026-05-11.